MannKind (MNKD) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Market Cap: $1.1BFounded: 1991Employees: 250-500HQ: Westlake Village, United States

Sector Ranking#49 in Drug Delivery & Formulation

Overview

MannKind Corporation has evolved from a development-stage entity into a commercial organization with a diversified portfolio anchored by its proprietary Technosphere® inhalation platform. The company's strategy combines the commercialization of its own products—Afrezza® (inhaled insulin) and V-Go®—with strategic partnerships, as evidenced by the success of Tyvaso DPI®, and targeted acquisitions like scPharmaceuticals (FUROSCIX®). With a focus on cardiometabolic and orphan lung diseases, MannKind aims to drive growth through label expansions, pediatric studies, and leveraging its validated platform for new therapeutic applications.

Cardiometabolic DiseasesOrphan Lung Diseases

Technology Platform

Proprietary Technosphere® inhalation technology, a dry-powder delivery platform using engineered FDKP particles for rapid pulmonary absorption of peptides and small molecules.

FDA Approved Drugs

1

AFREZZABLAJun 27, 2014

Opportunities

Significant growth potential from label expansion of Afrezza into pediatric populations, rapid commercialization of the acquired FUROSCIX asset, and further out-licensing of the validated Technosphere platform for new therapeutic applications.

The shift towards value-based and home-based care models favors products like FUROSCIX and needle-free Afrezza.

Risk Factors

Commercial execution risk remains high in competitive diabetes and heart failure markets.

Revenue growth is dependent on a small number of key products (Afrezza, FUROSCIX), and future platform partnerships are not guaranteed.

The company must successfully manage the integration of acquisitions and maintain a strong balance sheet.

Competitive Landscape

Faces intense competition in diabetes from large-cap pharma's injectable insulins and pumps. Differentiates via needle-free, ultra-rapid delivery. In PAH, partnered Tyvaso DPI competes on convenience versus nebulized therapies. FUROSCIX's primary competition is standard in-hospital IV diuresis, against which it offers a home-based alternative.